Example of CNS Drugs format
Recent searches

Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format Example of CNS Drugs format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access
recommended Recommended

CNS Drugs — Template for authors

Publisher: Springer
Categories Rank Trend in last 3 yrs
Psychiatry and Mental Health #29 of 502 -
Pharmacology (medical) #18 of 246 down down by 2 ranks
Neurology (clinical) #31 of 343 up up by 1 rank
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 339 Published Papers | 2925 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 06/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Bentham Science

Quality:  
High
CiteRatio: 10.5
SJR: 1.955
SNIP: 1.851
open access Open Access

Elsevier

Quality:  
High
CiteRatio: 6.3
SJR: 1.603
SNIP: 1.26
open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 6.4
SJR: 1.187
SNIP: 1.192
open access Open Access

SAGE

Quality:  
High
CiteRatio: 6.1
SJR: 1.333
SNIP: 1.061

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

4.786

14% from 2018

Impact factor for CNS Drugs from 2016 - 2019
Year Value
2019 4.786
2018 4.192
2017 4.206
2016 4.394
graph view Graph view
table view Table view

8.6

9% from 2019

CiteRatio for CNS Drugs from 2016 - 2020
Year Value
2020 8.6
2019 7.9
2018 7.5
2017 8.1
2016 9.5
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 14% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 9% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.565

3% from 2019

SJR for CNS Drugs from 2016 - 2020
Year Value
2020 1.565
2019 1.522
2018 1.553
2017 1.635
2016 1.819
graph view Graph view
table view Table view

1.775

19% from 2019

SNIP for CNS Drugs from 2016 - 2020
Year Value
2020 1.775
2019 1.486
2018 1.548
2017 1.4
2016 1.708
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 3% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 19% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

CNS Drugs

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

CNS Drugs

CNS Drugs promotes rational pharmacotherapy and effective patient management within the disciplines of clinical psychiatry and neurology by providing a regular program of review articles covering important issues in the drug treatment of psychiatric and neurological disorders....... Read More

Pharmacology (medical)

Psychiatry and Mental health

Clinical Neurology

Medicine

i
Last updated on
06 Jun 2020
i
ISSN
1172-7047
i
Impact Factor
High - 1.687
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SPBASIC
i
Citation Type
Author Year
(Blonder et al, 1982)
i
Bibliography Example
Beenakker CWJ (2006) Specular andreev reflection in graphene. Phys Rev Lett 97(6):067,007, URL 10.1103/PhysRevLett.97.067007

Top papers written in this journal

Journal Article DOI: 10.2165/00023210-200519001-00001
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review.
John W. Newcomer1
01 Jan 2005 - CNS Drugs

Abstract:

Increasing numbers of reports concerning diabetes, ketoacidosis, hyperglycaemia and lipid dysregulation in patients treated with second-generation (or atypical) antipsychotics have raised concerns about a possible association between these metabolic effects and treatment with these medications. This comprehensive literature r... Increasing numbers of reports concerning diabetes, ketoacidosis, hyperglycaemia and lipid dysregulation in patients treated with second-generation (or atypical) antipsychotics have raised concerns about a possible association between these metabolic effects and treatment with these medications. This comprehensive literature review considers the evidence for and against an association between glucose or lipid dysregulation and eight separate second-generation antipsychotics currently available in the US and/or Europe, specifically clozapine, olanzapine, risperi-done, quetiapine, zotepine, amisulpride, ziprasidone and aripiprazole. This review also includes an assessment of the potential contributory role of treatment-induced weight gain in conferring risk for hyperglycaemia and dyslipidaemia during treatment with different antipsychotic medications. Substantial evidence from a variety of human populations, including some recent confirmatory evidence in treated psychiatric patients, indicates that increased adiposity is associated with a variety of adverse physiological effects, including decreases in insulin sensitivity and changes in plasma glucose and lipid levels. Comparison of mean weight changes and relative percentages of patients experiencing specific levels of weight increase from controlled, randomised clinical trials indicates that weight gain liability varies significantly across the different second-generation antipsychotic agents. Clozapine and olanzapine treatment are associated with the greatest risk of clinically significant weight gain, with other agents producing relatively lower levels of risk. Risperidone, quetiapine, amisulpride and zotepine generally show low to moderate levels of mean weight gain and a modest risk of clinically significant increases in weight. Ziprasidone and aripiprazole treatment are generally associated with minimal mean weight gain and the lowest risk of more significant increases. Published studies including uncontrolled observations, large retrospective database analyses and controlled experimental studies, including randomised clinical trials, indicate that the different second-generation antipsychotics are associated with differing effects on glucose and lipid metabolism. These studies offer generally consistent evidence that clozapine and olanzapine treatment are associated with an increased risk of diabetes mellitus and dyslipidaemia. Inconsistent results, and a generally smaller effect in studies where an effect is reported, suggest limited if any increased risk for treatment-induced diabetes mellitus and dyslipidaemia during risperidone treatment, despite a comparable volume of published data. A similarly smaller and inconsistent signal suggests limited if any increased risk of diabetes or dyslipidaemia during quetiapine treatment, but this is based on less published data than is available for risperidone. The absence of retrospective database studies, and little or no relevant published data from clinical trials, makes it difficult to draw conclusions concerning risk for zotepine or amisulpride, although amisulpride appears to have less risk of treatment-emergent dyslipidaemia in comparison to olanzapine. With increasing data from clinical trials but little or no currently published data from large retrospective database analyses, there is no evidence at this time to suggest that ziprasidone and aripiprazole treatment are associated with an increase in risk for diabetes, dyslipidaemia or other adverse effects on glucose or lipid metabolism. In general, the rank order of risk observed for the second-generation antipsychotic medications suggests that the differing weight gain liability of atypical agents contributes to the differing relative risk of insulin resistance, dyslipidaemia and hyperglycaemia. This would be consistent with effects observed in nonpsychiatric samples, where risk for adverse metabolic changes tends to increase with increasing adiposity. From this perspective, a possible increase in risk would be predicted to occur in association with any treatment that produces increases in weight and adiposity. However, case reports tentatively suggest that substantial weight gain or obesity may not be a factor in up to one-quarter of cases of new-onset diabetes that occur during treatment. Pending further testing from preclinical and clinical studies, limited controlled studies support the hypothesis that clozapine and olanzapine may have a direct effect on glucose regulation independent of adiposity. The results of studies in this area are relevant to primary and secondary prevention efforts that aim to address the multiple factors that contribute to increased prevalence of type 2 diabetes mellitus and cardiovascular disease in populations that are often treated with second-generation antipsychotic medications. read more read less

Topics:

Atypical antipsychotic (59%)59% related to the paper, Olanzapine (56%)56% related to the paper, Quetiapine (55%)55% related to the paper, Amisulpride (55%)55% related to the paper, Antipsychotic (55%)55% related to the paper
1,420 Citations
Patent DOI: 10.2165/00023210-199912060-00001
Tyrosine kinase inhibitors
21 Oct 2002 - CNS Drugs

Abstract:

The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods o... The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals. read more read less

Topics:

Receptor tyrosine kinase (62%)62% related to the paper, ROR1 (60%)60% related to the paper, Platelet-derived growth factor receptor (58%)58% related to the paper, Tyrosine kinase (57%)57% related to the paper, Proto-oncogene tyrosine-protein kinase Src (57%)57% related to the paper
1,135 Citations
Journal Article DOI: 10.2165/00023210-200216100-00004
Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.
Emilio Perucca1
01 Jan 2002 - CNS Drugs

Abstract:

Thirty-five years since its introduction into clinical use, valproate (valproic acid) has become the most widely prescribed antiepileptic drug (AED) worldwide. Its pharmacological effects involve a variety of mechanisms, including increased γ-aminobutyric acid (GABA)-ergic transmission, reduced release and/or effects of excit... Thirty-five years since its introduction into clinical use, valproate (valproic acid) has become the most widely prescribed antiepileptic drug (AED) worldwide. Its pharmacological effects involve a variety of mechanisms, including increased γ-aminobutyric acid (GABA)-ergic transmission, reduced release and/or effects of excitatory amino acids, blockade of voltage-gated sodium channels and modulation of dopaminergic and serotoninergic transmission. read more read less

Topics:

Valproic Acid (53%)53% related to the paper, Anticonvulsant (52%)52% related to the paper
605 Citations
Journal Article DOI: 10.2165/00023210-200822050-00001
Internet addiction: definition, assessment, epidemiology and clinical management.
Martha Shaw1, Donald W. Black1
01 May 2008 - CNS Drugs

Abstract:

cupations, urges or behaviours regarding computer use and internet access that lead to impairment or distress. The condition has attracted increasing attention in the popular media and among researchers, and this attention has paralleled the growth in computer (and Internet) access. Prevalence estimates vary widely, although ... cupations, urges or behaviours regarding computer use and internet access that lead to impairment or distress. The condition has attracted increasing attention in the popular media and among researchers, and this attention has paralleled the growth in computer (and Internet) access. Prevalence estimates vary widely, although a recent random telephone survey of the general US population reported an estimate of 0.3–0.7%. The disorder occurs worldwide, but mainly in countries where computer access and technology are widespread. Clinical samples and a majority of relevant surveys report a male preponderance. Onset is reported to occur in the late 20s or early 30s age group, and there is often a lag of a decade or more from initial to problematic computer usage. Internet addiction has been associated with dimensionally measured depression and indicators of social isolation. Psychiatric co-morbidity is common, particularly mood, anxiety, impulse control and substance use disorders. Aetiology is unknown, but probably involves psychological, neurobiological and cultural factors. There are no evidence-based treatments for internet addiction. Cognitive behavioural approaches may be helpful. There is no proven role for psychotropic medication. Marital and family therapy may help in selected cases, and online self-help books and tapes are available. Lastly, a self-imposed ban on computer use and Internet access may be necessary in some cases. read more read less

Topics:

Computer addiction (65%)65% related to the paper, The Internet (54%)54% related to the paper, Addiction (53%)53% related to the paper, Population (52%)52% related to the paper, Social isolation (51%)51% related to the paper
577 Citations
Journal Article DOI: 10.2165/00023210-200216100-00003
Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.
01 Jan 2002 - CNS Drugs

Abstract:

Since its first marketing as an antiepileptic drug (AED) 35 years ago in France, valproate has become established worldwide as one of the most widely used AEDs in the treatment of both generalised and partial seizures in adults and children. The broad spectrum of antiepileptic efficacy of valproate is reflected in preclinical... Since its first marketing as an antiepileptic drug (AED) 35 years ago in France, valproate has become established worldwide as one of the most widely used AEDs in the treatment of both generalised and partial seizures in adults and children. The broad spectrum of antiepileptic efficacy of valproate is reflected in preclinical in vivo and in vitro models, including a variety of animal models of seizures or epilepsy. read more read less

Topics:

Epilepsy (59%)59% related to the paper, Valproic Acid (56%)56% related to the paper, Vigabatrin (54%)54% related to the paper, Status epilepticus (51%)51% related to the paper, Anticonvulsant (51%)51% related to the paper
565 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for CNS Drugs.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

CNS Drugs format uses SPBASIC citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write CNS Drugs in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the CNS Drugs guidelines and auto format it.

2. Do you follow the CNS Drugs guidelines?

Yes, the template is compliant with the CNS Drugs guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in CNS Drugs?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the CNS Drugs citation style.

4. Can I use the CNS Drugs templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for CNS Drugs.

5. Can I use a manuscript in CNS Drugs that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper CNS Drugs that you can download at the end.

6. How long does it usually take you to format my papers in CNS Drugs?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in CNS Drugs.

7. Where can I find the template for the CNS Drugs?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per CNS Drugs's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the CNS Drugs's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. CNS Drugs an online tool or is there a desktop version?

SciSpace's CNS Drugs is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like CNS Drugs?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like CNS Drugs?”

11. What is the output that I would get after using CNS Drugs?

After writing your paper autoformatting in CNS Drugs, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is CNS Drugs's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for CNS Drugs?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for CNS Drugs. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In CNS Drugs?

The 5 most common citation types in order of usage for CNS Drugs are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the CNS Drugs?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per CNS Drugs's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download CNS Drugs in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in CNS Drugs Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to CNS Drugs formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template